Jinan Liangfu Jinghe Pharmaceutical Technology Co., Ltd.
MAILBOX | CHINESE | ENGLISH
Products
API & Intermediates
Cell Signaling Pathway Inhibitors
·Inhibitors of BTK Pathway
·Inhibitors of EGFR pathways
·Inhibitors of VEGFR pathways
·Inhibitors of PDGFR pathways
·Inhibitors of PI3K-Akt-mTOR pathways
·Inhibitors of IGF pathways
·Inhibitors of JAK-STAT pathway
·Inhibitors of MAPK/ERK pathway
·Inhibitors of apoptosis pathway
·Inhibitors of HIF-1 pathway
·Inhibitors of other pathways
Small Molecule Compounds
Impurity Reference Standards
Others
Contact Us
Address: 2766 Yingxiu Road, Jinan High-Tech Zone, China
Tel:
Sales: +86-531-88811783
Evaluation:+86-531-88806178
R&D: +86-531-88813691
Office: +86-531-88817621
Fax: +86-531-88817925
Zip Code: 250101
Email:
Trade Department:
sales@trio-pharmatech.com
G&D&E:
register@trio-pharmatech.com
yzxpj@trio-pharmatech.com
R&D center::
newdrugs@trio-pharmatech.com
Cell Signaling Pathway Inhibitors Now Position:Home > Products > Cell Signaling Pathway Inhibitors < Inhibitors of other pathways
ABT-199(CAS:1257044-40-8)

Product No.

TP1137A

Name

ABT-199

Synonyms

AbbVie, 4-[4-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-benzamide

CAS Number

1257044-40-8

Structure

Brief Description

ABT-199 (GDC-0199) is a Bcl-2-selective inhibitor with Ki of <0.01 nM, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

Purity

>99%

Package

5mg10mg20mg50mg

 





Close
QQ1: 1762738062
QQ2: 1919147143
MSN: sales-trio
SKYPE: janisa.yan